Trial Profile

A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of Oral Omadacycline and Oral Nitrofurantoin in the Treatment of Female Adults With Cystitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omadacycline (Primary) ; Nitrofurantoin
Indications Cystitis; Urinary tract infections
Focus Adverse reactions; Therapeutic Use
Sponsors Paratek Pharmaceuticals

Most Recent Events

25 Oct 2020 Results presented at the IDWeek 2020
21 Oct 2020 According to a Paratek Pharmaceuticals media release, data are being presented at the IDWeek 2020 virtual meeting.
31 Oct 2019 According to a Paratek Pharmaceuticals media release, additional analyses are ongoing and the company plans on presenting data from the study at a future medical conference.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com